Cargando…

Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials

PURPOSE: To quantify clinical trial participants’ and investigators’ judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence. METHODS: Discrete-choice experiment surveys w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katz, Eva G, Hauber, Brett, Gopal, Srihari, Fairchild, Angie, Pugh, Amy, Weinstein, Rachel B, Levitan, Bennett S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085312/ https://www.ncbi.nlm.nih.gov/pubmed/27799749 http://dx.doi.org/10.2147/PPA.S114172

Ejemplares similares

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
por: Blackwood, Clifton, et al.
Publicado: (2020)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Desai, Mitesh, et al.
Publicado: (2018)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
por: Blackwood, Clifton, et al.
Publicado: (2020)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
por: Patel, Maxine X., et al.
Publicado: (2020)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015)

Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
por: Robinson, Delbert G., et al.
Publicado: (2023)

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
por: Paton, Carol, et al.
Publicado: (2022)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey
por: Liu, Chun-Hao, et al.
Publicado: (2018)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

The Value of Hope: Patients’ and Physicians’ Preferences for Survival in Advanced Non-Small Cell Lung Cancer
por: Hauber, Brett, et al.
Publicado: (2020)

Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa
por: Roopun, Krishanand R., et al.
Publicado: (2020)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
por: Hýža, Martin, et al.
Publicado: (2021)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu, Lin-Ling, et al.
Publicado: (2019)

Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections
por: Nilsson, Björn M., et al.
Publicado: (2017)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8va65tvkmvvi5rbaskdu5de6me